Akebia Therapeutics, Inc. (AKBA)
| Market Cap | 379.08M |
| Revenue (ttm) | 236.20M |
| Net Income (ttm) | -5.35M |
| Shares Out | 267.90M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,085,958 |
| Open | 1.440 |
| Previous Close | 1.420 |
| Day's Range | 1.410 - 1.459 |
| 52-Week Range | 1.140 - 4.079 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 5.25 (+271.03%) |
| Earnings Date | May 7, 2026 |
About AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia... [Read more]
Financial Performance
In 2025, Akebia Therapeutics's revenue was $236.20 million, an increase of 47.46% compared to the previous year's $160.18 million. Losses were -$5.35 million, -92.30% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AKBA stock is "Strong Buy." The 12-month stock price target is $5.25, which is an increase of 271.03% from the latest price.
News
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, g...
Akebia Therapeutics Transcript: R&D Day 2026
The company is advancing a differentiated pipeline in kidney disease, with praliciguat, AKB-097, and AKB-9090 progressing through key clinical milestones. Vafseo is driving revenue growth, supporting R&D investments, and multiple catalysts are expected in the next year.
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is focused on making Vafseo the standard of care for dialysis-related anemia, supported by strong clinical and economic data, and is expanding its kidney disease pipeline with praliciguat and AKB-097. Post-TDAPA, pricing will align with ESA benchmarks, targeting a $1B market.
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics Earnings Call Transcript: Q4 2025
Net product revenues grew nearly 50% year-over-year to $236.2 million in 2025, driven by Vafseo's launch and Auryxia sales, while net loss narrowed significantly. Vafseo adoption is expanding, with improved adherence and broader access, and the pipeline is advancing with multiple clinical milestones ahead.
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
Q4 2025 net product revenues of $54.3 million ; 2025 full-year net product revenues of $227.3 million , representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo®...
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December...
Akebia Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The company is advancing its kidney disease portfolio, with VAFSEO gaining traction in dialysis anemia and new dosing strategies reducing discontinuation rates. Key clinical readouts for VAFSEO and pipeline assets like praliciguat and AKB-097 are expected over the next 12–24 months.
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomer...
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is expanding its kidney disease portfolio with new pipeline assets and a successful Vafseo launch, despite operational and pricing challenges. Clinical data supports Vafseo's benefits, and new acquisitions strengthen the rare disease pipeline.
Akebia Announces Establishment of Rare Kidney Disease Pipeline
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease ind...
Q32 Bio Sells Complement Inhibitor ADX-097
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash ru...
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Vafseo's launch in the dialysis market is progressing, with expanding access and operational improvements expected to drive growth into 2026. Clinical data supports its efficacy and safety, while new dosing strategies and ongoing studies aim to establish it as standard of care.
Akebia Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Vafseo's U.S. launch has expanded patient access significantly, with DaVita and U.S. Renal Care as key partners. Recent clinical data show reduced mortality and hospitalization, supporting broader adoption. Financially, the company is well-capitalized and advancing a robust pipeline.
Akebia Therapeutics Earnings Call Transcript: Q3 2025
Vafseo prescriptions outpaced recent dialysis launches, with Q3 revenue at $14.3M and total company revenue up 57% year-over-year. Operational challenges are being addressed, and prescribing access is set to expand to over 260,000 patients by year-end, supporting long-term growth.
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million ; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourt...
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025
Akebia Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...